AveXis steps up gene therapy pursuit of Biogen’s SMA pathfinder – FierceBiotech
FierceBiotech |
AveXis steps up gene therapy pursuit of Biogen's SMA pathfinder
FierceBiotech AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug. The Chicago biotech already has … AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy AveXis (NASDAQ:AVXS) PT Set at $122.00 by UBS Group Chardan Capital Reiterates Buy Rating for AveXis (NASDAQ:AVXS) |
